// App-Quantinova.ai

5009 : Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).

Researchers

Presenter

  • Dana E. Rathkopf

Principal Investigators

  • Johann Sebastian De Bono

  • Scott A. North

  • Yves Fradet

  • Thomas W. Griffin

  • Youn Choi Park

  • Thian San Kheoh

  • Eric Jay Small

  • Howard I. Scher

  • Arturo Molina

  • Charles J. Ryan

  • Christopher Logothetis

  • Neal Shore

  • Paul L. De Souza

  • Karim Fizazi

  • Peter Mulders

  • Paul N. Mainwaring

  • John D Hainsworth

  • Tomasz M. Beer

Medical Centers

  • Radboud University Medical Center, Njmegen, Netherlands

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Haematology and Oncology Clinics of Australia, Brisbane, Australia

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Sarah Cannon Research Institute, Nashville, TN

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • University of Western Sydney School of Medicine and Ingham Institute, Liverpool, Australia

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Laval University, Quebec, Quebec, Canada.

Locations

  • Canada

  • Netherlands

  • United Kingdom

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00887198

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved